In-Body CAR-T therapy takes aim at Hard-to-Treat blood cancer
Disease control
Not yet recruiting
This early-phase study tests the safety of a new immunotherapy that creates cancer-fighting cells inside the body for people with relapsed or refractory plasma cell neoplasms, a type of blood cancer. The treatment targets two proteins (BCMA and GPRC5D) on cancer cells. Researcher…
Phase: EARLY_PHASE1 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC